Brii Biosciences Limited (7SS) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-9.36x
Brii Biosciences Limited (7SS) has a Cash Flow-to-Debt Ratio of -9.36x as of December 2025, meaning its operating cash flow of €-338.81 Million could theoretically repay -9% of its total liabilities (€36.20 Million) in one year. See how financially flexible is Brii Biosciences Limited to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-9.36x
Operating CF / Total Liabilities
Operating Cash Flow
€-338.81 Million
EUR
Total Liabilities
€36.20 Million
EUR
Data as of
Dec 2025
Most recent filing
Brii Biosciences Limited Cash Flow-to-Debt Ratio (2020–2025)
Historical debt coverage capacity for Brii Biosciences Limited across 6 annual periods. For the full cash flow conversion analysis, see 7SS cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Brii Biosciences Limited (2020–2025)
Year-by-year debt coverage analysis for Brii Biosciences Limited.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -9.36x | €-338.81 Million | €36.20 Million | ▼ -152.3% |
| 2024 | -3.71x | €-372.89 Million | €100.55 Million | ▲ +21.4% |
| 2023 | -4.72x | €-594.01 Million | €125.87 Million | ▼ -122.9% |
| 2022 | -2.12x | €-496.28 Million | €234.35 Million | ▲ +27.7% |
| 2021 | -2.93x | €-879.46 Million | €300.44 Million | ▼ -2082.9% |
| 2020 | -0.13x | €-403.72 Million | €3.01 Billion | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.